Abstract. In the third edition of the Huntington's Disease Clinical Trials Corner we list all currently registered and ongoing clinical trials, expand on the SIGNAL trial (NCT02481674), and cover the recently finished CREST-E trial (NCT00712426).
INTRODUCTION
The Huntington's Disease Clinical Trials Corner is a regular section devoted to highlighting ongoing and recently completed clinical trials in Huntington's disease (HD). Clinical trials previously reviewed by the Huntington's Disease Clinical Trials Corner are listed in Table 1 .
In this edition, we highlight the SIGNAL trial (NCT02481674) [1] , and summarise the results of the recently published CREST-E trial (NCT00712426) [2, 3] . Finally we tabulate all currently registered and ongoing clinical trials in Tables 2 to 4 . For further details on the methodology used, please refer to the September 2017 edition of Huntington's Disease Clinical Trials Corner [4] .
If you would like to draw attention to specific trials, please feel free to email us at: f.rodrigues@ucl.ac.uk and e.wild@ucl.ac.uk.
ONGOING CLINICAL TRIALS
A list of all ongoing clinical trials is given in Tables 2-4 . * Correspondence to: Edward J. Wild, UCL Huntington's Disease Centre, Russell Square 10-12, London, WC1B 5EH, UK. E-mail: e.wild@ucl.ac.uk.
SIGNAL (NCT02481674)
Study title VX15/2503 Treatment for Huntington's Disease (SIGNAL) [1] .
Intervention
VX15/2503 (20 mg/kg), an anti-semaphorin 4D antibody [5] .
Description
The SIGNAL trial, sponsored by Vaccinex (Rochester, NY, USA), aims to evaluate the safety, tolerability, pharmacokinetics and efficacy of monthly intra-venous VX15/2503 in adults (≥21 years of age) with late prodromal (i.e. a CAG-age Product superior to 200 and a Unified Huntington's Disease Rating Scale [UHDRS] Diagnostic Confidence Level of 2 or 3) and early manifest HD (i.e. a UHDRS Diagnostic Confidence Level of 4 and a UHDRS Total Functional Capacity [TFC] above or equal to 11), comparing with intra-venous placebo, for disease modification.
This trial is phase 2, multi-centre, national, randomized, placebo controlled, double-blind, parallel study. It is divided into cohort A and cohort B, and will involve 240 participants. Cohort A recruited 36 participants and was completed in December 2015. 
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Sponsors/funders
Vaccinex Inc., and the Huntington Study Group.
Comments
Semaphorins are a family of proteins whose name derives from semaphore (from the Greek for signbearer). Initially described as signalling proteins for neuronal growth and regeneration, today they are known to be involved in many other processes such as the immune response. Semaphorin 4D, or CD100, is an axon-guiding molecule, and a B and T cell modulator.
In a YAC128 transgenic Huntington's disease mouse model, targeting semaphorin 4D with monoclonal antibodies seemed to ameliorate striatal cortical and corpus callosum atrophy, and behavioural phenotype [6] . However, as of today, there is no published evidence supporting that the semaphorin family may be a therapeutic target in humans with HD.
Previous clinical trials involving 42 patients with advanced solid tumours (4 weekly doses up to 20 mg/kg per week) [7] and 50 patients with multiple sclerosis (single ascending dose up to 20 mg/kg) [8] showed VX15/2503 to be relatively well tolerated and safe, but were neither designed nor powered to assess clinical benefit.
Preliminary data from SIGNAL's Cohort A have been presented at public meetings by Vaccinex, reporting interesting neuroimaging and neurometabolic results (PET imaging) in the VX15/2503 arm. Previous reports of atrophy slowing in HD have not ultimately been associated with clinical benefit or slowing of clinical progression [9] [10] [11] , so such reports need to be treated with caution and interpreted in their full context.
COMPLETED CLINICAL TRIALS
CREST-E (NCT00712426)
Study title
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease [2, 3] .
Intervention
Creatine monohydrate, a nutritional supplement.
Description
The goal of CREST-E trial was to assess the effects of up to 40 gm of oral creatine monohydrate daily compared with oral placebo on functional decline in adults with early manifest HD (i.e. motor signs characteristic of HD plus a positive family history for HD or a HTT CAG repeat length ≥36 plus a UHDRS Total Functional Capacity ≥7). This trial was a phase 3, multi-centre, international, randomized, placebo-controlled, double-blind, parallel study. Although designed to recruit 650 participants from Australia, Canada, New Zealand, and the United States, the trial only recruited 553 participants before being halted for futility after an interim analysis. Participant involvement lasted for up to 48 months.
The primary outcome was rate of change from baseline in the UHDRS TFC at weeks 12 to 48 depending on each participant's date of enrolment. The secondary outcomes included changes in other UHDRS scores, adverse events, tolerability, quality of life, and several biofluid and imaging biomarkers.
Sponsors/funders
Massachusetts General Hospital, University of Rochester, National Center for Complementary and Integrative Health.
Results
The trial was completed on December 2014 and the results published in July 2017 [2] . CREST-E was the largest clinical trial undertaken in HD. The results showed that although no major safety concerns were noted apart from an increased risk of diarrhoea. Creatine did not have an effect on functional decline in HD, nor on any other outcome studied.
Creatine has previously been studied in presymptomatic and symptomatic individuals. In PRECREST (NCT00592995) [9, 12] 64 premanifest and at-risk individuals were enrolled in a 6-month randomized placebo-controlled double-blinded study of up to 15 gm of oral creatine monohydrate bid, followed by a 12-months open-label extension period. In CREST-HD (NCT00026988) [13, 14] 69 people with manifest HD were enrolled in a 16-week randomized placebo-controlled double-blinded study of 4 gm of oral creatine monohydrate bid.
As in CREST-E, no safety concerns emerged in PRECREST apart from increased risk of nausea and diarrhoea, but there was no change in clinical measures.
Further creatine clinical trials have been registered and the recruitment is completed (Pre-CREST-X [NCT01411150], Pre-CREST-X2 [NCT01411163], CREST-X [NCT01412151]) but to our knowledge, their results are not public yet.
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